DNA Sciences Partners With Bristol-Myers Squibb To Investigate Potential Disease Association Of Target Gene

10-Oct-2001

Bristol Myers-Squibb Company (NYSE: BMS) will partner with DNA Sciences, Inc. to investigate genetic variants within a potential drug discovery gene target. Under terms of the agreement, DNA Sciences will use its flexible, high-throughput sequencing and genotyping facility to study the novel Bristol-Myers Squibb gene in normal and affected disease populations. Both companies will utilize the research findings in their future research and development activities. Financial terms of the research agreement were not disclosed.

"Our effort with Bristol-Myers Squibb is a continuation of DNA Sciences' work to apply genetics to pharmaceutical discovery and development," said Steven B. Lehrer, president and chief operating officer at DNA Sciences. "DNA Sciences is working closely with Bristol-Myers Squibb to determine which genetic variations are associated with disease and potentially drug response."

https://www.chemeurope.com/en/news/5348/dna-sciences-partners-with-bristol-myers-squibb-to-investigate-potential-disease-association-of-target-gene.html